Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig + Daratumumab vs DRd in Newly Diagnosed Multiple Myeloma
NCT07095452Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Primary completion
- Mar 2041
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of etentamig in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Jan 2026; status: recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07095452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095452.